Peregrine Pharmaceuticals, Inc. (PPHM) Misses Q2 Loss Views; Revs Stronger
Tweet
Share
E-mailGet Alerts PPHM Hot Sheet
Join SI Premium – FREE
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) reported Q2 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $4.23 million versus the consensus estimate of $2.08 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Pulmatrix (PULM) Reports Q2 Loss of $0.29
- Omega Flex (OFLX) Tops Q2 EPS by 27c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
